You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,728,523


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,728,523
Title:Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
Abstract: The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.
Inventor(s): Attawia; Mohamed (Holmdel, NJ), DiMauro; Thomas M. (Southboro, MA), Serhan; Hassan (South Easton, MA), Kadiyala; Sudhakar (Newton, MA), Urbahns; David (Barrington, RI), Bruder; Scott (Franklin Lakes, NJ)
Assignee: DePuy Synthes Products, LLC (Raynham, MA)
Application Number:12/291,378
Patent Claims:1. A method of inhibiting degeneration of an extracellular matrix of a nucleus pulposus of an intervertebral disc having a degenerating nucleus pulposus and an annulus fibrosus in a patient in need thereof, comprising transdiscally administering into the degenerating nucleus pulposus an effective amount of a formulation comprising a highly specific cytokine antagonist that inhibits tumor necrosis factor-.alpha. (TNF-.alpha.), wherein said highly specific cytokine antagonist is released from a sustained release device comprising a hydrogel, thereby effectively inhibiting the degeneration of the extracellular matrix of the degenerating nucleus pulposus of the intervertebral disc.

2. The method of claim 1, wherein said highly specific cytokine antagonist is a monoclonal antibody.

3. A method of inhibiting degeneration of an extracellular matrix of a nucleus pulposus of an intervertebral disc having a degenerating nucleus pulposus in a patient in need thereof, comprising transdiscally administering into the degenerating nucleus pulposus an effective amount of a formulation comprising infliximab, wherein said infliximab is released from a a sustained release device comprising a hydrogel, thereby effectively inhibiting the degeneration of the extracellular matrix of the degenerating nucleus pulposus of the intervertebral disc.

4. The method of claim 2, wherein said monoclonal antibody binds membrane-bound TNF-.alpha..

5. The method of claim 2, wherein said monoclonal antibody binds soluble TNF-.alpha..

6. The method of claim 1, wherein said highly specific cytokine antagonist is released from said formulation by its diffusion through said sustained delivery device.

7. The method of claim 1, wherein said highly specific cytokine antagonist is released from said formulation by biodegradation of said sustained delivery device.

8. The method of claim 1, wherein the sustained release device provides controlled release.

9. The method of claim 1, wherein the sustained release device provides continuous release.

10. The method of claim 1, wherein the sustained release device provides intermittent release.

11. The method of claim 1, wherein the sustained release device comprises a biosensor.

12. The method of claim 1, wherein the sustained release device comprises a plurality of microspheres.

13. The method of claim 1, wherein said sustained release device is adapted to remain in said intervertebral disc for at least 1 month.

14. The method of claim 13, wherein said sustained release device is adapted to remain in said intervertebral disc for at least 2 months.

15. The method of claim 14, wherein said sustained release device is adapted to remain in said intervertebral disc for at least 6 months.

16. The method of claim 1, wherein the formulation is provided closely adjacent to the outer wall of the annulus fibrosus.

17. The method of claim 1, further comprising removing a portion of the nucleus pulposus prior to administering an effective amount of said formulation.

18. The method of claim 1, wherein said formulation is administered in a volume of between 0.03 ml and 1.0 ml.

19. A method of treating degenerative disc disease in an intervertebral disc having a nucleus pulposus and an annulus fibrosus in a patient in need thereof, comprising transdiscally administering into an intervertebral disc an effective amount of a formulation comprising a highly specific cytokine antagonist that inhibits tumor necrosis factor-.alpha. (TNF-.alpha.), wherein said highly specific cytokine antagonist is (a) administered in an amount effective to inhibit degradation of an extracellular matrix of the nucleus pulposus and (b) released from a sustained release device, wherein said sustained release device comprises a hydrogel, thereby effectively treating the degenerative disc disease in the intervertebral disc.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.